Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: A prospective case series

Clinical and Experimental Ophthalmology

Volumn 36, Issue 5, 2008, Pages 449-454

  Yeoh, Jonathan ^a   Williams, Christopher ^a   Allen, Penny ^a   Buttery, Robert ^a   Chiu, Daniel ^a   Clark, Ben ^a   Essex, Rohan ^a   Mccombe, Mark ^a   Qureshi, Salmaan ^a   Campbell, William G ^a  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

Avastin; Proliferative diabetic retinopathy; Tractional retinal detachment; Vitrectomy; Vitreous haemorrhage

Indexed keywords

BEVACIZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE STUDY; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DISEASE SEVERITY; ENDOPHTHALMITIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; SINGLE DRUG DOSE; UVEITIS; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RETINAL DETACHMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 50849109818     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2008.01805.x     Document Type: Article

References (13)

1. Michels S, Rosenfield P, Puliafito C et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-47.
2. Avery R, Piemarici D, Rabena M et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
3. Rich R, Rosenfeld P, Puliafito C et al. Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
4. Chen E, Park C. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26: 699-70.
5. Avery R, Pearlman J, Piemarici D et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-705.
6. Spaide R, Fisher Y. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous haemorrhage. Retina 2006; 26: 275-8.
7. Mason J, Nixon P, White M. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 685-8.
8. Isaacs T, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab. Clin Experiment Ophthalmol 2006; 34: 802-5.
9. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial. DRVS report 4. Ophthalmology 1988; 95: 1321-34.
10. Yeh PT, Yang CM, Yang CH, Huang JS. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous haemorrhage. Ophthalmology 2005; 112: 2095-102.
11. West J, Gregor Z. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol 2000; 84: 822-5.
12. Schiff WM, Barile GR, Hwang JC et al. Diabetic vitrectomy. Influence on lens status upon anatomic and visual outcomes. Ophthalmology 2007; 114: 544-50.
13. Bakri S, Snyder M, Reid J et al. Pharmacokinetics of intravitreal bevacizumab. Ophthalmology 2007; 114: 855-9.